Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Stephanie B. Hastings
Observed names:
Hastings, Stephanie B.,
Stephanie B Hastings,
Stephanie Hastings
Institution:
LabCorp (United States)
Observed institution:
LabCorp (United States)
OpenAlex ID:
A5005757322
Cancer testis antigen burden (CTAB): a novel biomarker of tumor-associated antigens in lung cancer
2024
·
R. J. Seager
, Maria-Fernanda Senosain
, et al.
·
Journal of Translational Medicine
·
19
PDF
Comprehensive Assessment of Immune Phenotype and Its Effects on Survival Outcomes in HER2-Low versus HER2-Zero Breast Cancer
2024
·
Heidi Ko
, RJ Seager
, et al.
·
Breast Cancer Targets and Therapy
·
7
PDF
Real-world comprehensive genomic and immune profiling reveals distinct age- and sex-based genomic and immune landscapes in tumors of patients with non-small cell lung cancer
2024
·
Zachary D. Wallen
, Heidi Ko
, et al.
·
Frontiers in Immunology
·
5
PDF
Validation of the Labcorp Plasma Focus Test to Facilitate Precision Oncology Through Cell-Free DNA Genomic Profiling of Solid Tumors
2023
·
Ellen L. Verner
, Jennifer B. Jackson
, et al.
·
Journal of Molecular Diagnostics
·
5
Abstract 3114: Analytical validation of Illumina's TruSight Oncology 500 ctDNA assay
2020
·
Kirsten C. Verhein
, Gunjan Hariani
, et al.
·
Cancer Research
·
5
Interaction between VEGF-A and immune checkpoint targets in triple-negative breast cancer and mechanisms of immune evasion and tumor progression.
2024
·
R.J. Seager
, Sarabjot Pabla
, et al.
·
Journal of Clinical Oncology
·
4
Pervasive loss of antigen presentation in solid tumors driven by loss of HLA class I expression.
2024
·
Sarabjot Pabla
, Heidi Chwan Ko
, et al.
·
Journal of Clinical Oncology
·
1
P072: Complementary germline and somatic testing in breast cancer care
2026
·
Sarah Nielsen Young
, Emily Russell
, et al.
·
Genetics in Medicine Open
1347 AI-powered image-based spatial profiling of MET-mutated non-small cell lung cancer identifies immune-active MET exon 14 skipping subtypes as potential immunotherapy targets
2025
·
Zachary D Wallen
, Yoojoo Lim
, et al.
·
Journal for ImmunoTherapy of Cancer
PDF
149 Machine-learning aided biomarker integration reveals emergent tumor-immune groups within real-world patient data and facilitates inference of tumor-immune balance as it affects immunotherapy response
2025
·
Robert Seager
, Zachary D Wallen
, et al.
·
Journal for ImmunoTherapy of Cancer
PDF
1278 Immune gene expression differences in HPV-positive and HPV-negative non-nasopharyngeal head and neck cancer offer potential for tumor classification by HPV status
2025
·
Zachary D Wallen
, Tobias Meissner
, et al.
·
Journal for ImmunoTherapy of Cancer
PDF
Abstract A019: Analytical validation of homologous recombination deficiency (HRD) status in patients with ovarian cancer using the OmniSeq® INSIGHT (OSI) test
2025
·
Jie An
, Hardik I. Parikh
, et al.
·
Cancer Research
Abstract P3-01-24: Triple negative and non-triple negative breast cancer have distinct metabolic characteristics associated with divergent survival outcomes
2025
·
Sarabjot Pabla
, Shipra Gandhi
, et al.
·
Clinical Cancer Research
Abstract 3401: Pharmacogenomic landscape of UGT1A1 in cancer patients from the Avera Sequencing and Analytics Protocol (ASAP) registry
2025
·
Kobina A. Amoah
, Crystal Hattum
, et al.
·
Cancer Research
1403 Comparison of tumor immune microenvironment (TME) between primary and metastatic upper gastrointestinal (GI) adenocarcinoma
2024
·
Robert Seager
, Sarabjot Pabla
, et al.
·
Journal for ImmunoTherapy of Cancer
A consensus-based classification workflow to determine genetically inferred ancestry from comprehensive genomic profiling of patients with solid tumors
2024
·
Zachary D Wallen
, Mary K Nesline
, et al.
·
Briefings in Bioinformatics
PDF
Novel HLA-Ilo/HLA-IIhi phenotype and immune evasion in triple-negative breast cancer.
2024
·
Heidi Chwan Ko
, R.J. Seager
, et al.
·
Journal of Clinical Oncology
PDF
Evaluating tumor inflammation and PD-L1 expression in sequential biopsies of real-world primary and metastatic breast cancer.
2024
·
Zachary D. Wallen
, Sarabjot Pabla
, et al.
·
Journal of Clinical Oncology
Comprehensive genomic and immune profiling of non-V600 BRAF-mutated melanomas: Implications for therapeutic strategies beyond BRAF/MEK inhibitors.
2024
·
Maria-Fernanda Senosain
, Sarabjot Pabla
, et al.
·
Journal of Clinical Oncology
PDF
175 Metastatic triple negative breast cancer has distinct tumor immune landscape
2023
·
Robert Seager
, Heidi Ko
, et al.
·
Journal for ImmunoTherapy of Cancer
PDF
176 Immune microenvironment of primary versus metastatic melanoma of the brain
2023
·
Maria-Fernanda Senosain
, Heidi Ko
, et al.
·
Journal for ImmunoTherapy of Cancer
PDF
184 Distinct immunotherapy immune response phenotypes in non-small cell lung cancer present with unique genomic alteration profiles
2023
·
Zachary D Wallen
, RJ Seager
, et al.
·
Journal for ImmunoTherapy of Cancer
PDF
183 Comprehensive genomic and immune profiling (CGIP) reveals a distinct genomic and immune gene expression profile for younger patients with non-small cell lung cancer (NSCLC)
2023
·
Zachary D Wallen
, Heidi Ko
, et al.
·
Journal for ImmunoTherapy of Cancer
PDF
Abstract 1346: Panel-based tumor mutational burden (TMB) analysis of matched tumor and plasma specimens using Illumina’s TruSight Oncology 500 next-generation sequencing assay
2019
·
Stephanie B. Hastings
, Gunjan Hariani
, et al.
·
Cancer Research
Abstract 1346: Panel-based tumor mutational burden (TMB) analysis of matched tumor and plasma specimens using Illumina’s TruSight Oncology 500 next-generation sequencing assay
2019
·
Stephanie B. Hastings
, Gunjan Hariani
, et al.
·
Clinical Research (Excluding Clinical Trials)
Show more works
View as search
Works count:
33
Citation count:
46
H-index:
5
I10-index:
1
Year
Topic
Type